Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444677 | 0.95 | MEN1 (0.44) | DRD2MTNR1AMTNR1BDRD3MEN1 | |
| SCHEMBL17444553 | 0.93 | DRD2 (0.46) | DRD2MTNR1AMTNR1BDRD3MEN1 | |
| SCHEMBL17444698 | 0.90 | KMT2A (0.49) | MEN1KMT2ACNR2 | |
| SCHEMBL17444558 | 0.90 | DRD2 (0.48) | DRD2DRD3MEN1KMT2ACNR2 | |
| SCHEMBL17444551 | 0.88 | MEN1 (0.42) | DRD2MTNR1AMTNR1BDRD3MEN1 | |
| SCHEMBL17444594 | 0.86 | MEN1 (0.46) | DRD2DRD3MEN1KMT2AALDH1A1 | |
| SCHEMBL17444681 | 0.86 | KMT2A (0.50) | DRD2MEN1KMT2ACNR2 | |
| SCHEMBL17444675 | 0.85 | MEN1 (0.50) | MEN1KMT2ACNR2LMNA | |
| SCHEMBL17444613 | 0.84 | MEN1 (0.49) | DRD2DRD3MEN1KMT2AALDH1A1 | |
| SCHEMBL17444611 | 0.84 | SIGMAR1 (0.49) | DRD2DRD3MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| EP-3169683-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | DRD2 3744/4885MTNR1A 1786/4885MTNR1B 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.